Groupe SAIDAL is a joint stock company with a capital of 2,500,000,000 Algerian dinars. 80% of the capital is held by the State, and the remaining 20% was sold through the stock exchange in 1999 to institutional investors and individuals. The company operates as an Industrial Group with the purpose of developing, producing, and marketing pharmaceutical products for both human and veterinary use. Groupe SAIDAL's strategic objective is to strengthen its position as a leader in the production of generic drugs and to contribute to the implementation of the national drug policy. Founded in 1982, the company operates within the Manufacturing, Pharmaceutical, and Marketing industries. As of now, no specific details about the latest investment or the investors involved are available.
There is no investment information
No recent news or press coverage available for Groupe SAIDAL.
We care about your data, and we'd love to use cookies make your experience better.